First patient enrolled in a Phase 2 Study in T2DM patients with Olatec's NLRP3 inhibitor dapansutrileThe first patient with T2DM and diabetes-related complications has been enrolled in the clinical trial, DAPAN-DIA, in Basel, Switzerland,...
EMA issues recommendations for GLP-1ra to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedationEuropean Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended new measures to minimise the risk of...
Phenomix launches personalised obesity care genetic testing available to women in with Hello Alpha partnershipPhenomix Sciences has entered a partnership with Hello Alpha, a virtual primary care platform, to enable women to take control of their...
Amylyx acquires avexitide GLP-1ra post-bariatric hypoglycaemia from Eiger BioPharmaceuticalsAmylyx Pharmaceuticals has acquired avexitide from Eiger BioPharmaceuticals, an investigational, first-in-class glucagon-like peptide-1...
Biophytis obtains IND approval to start its phase 2 OBA study in obesityBiophytis has received Investigational New Drug (IND) approval from the FDA for its phase 2 OBA clinical study in obesity with BIO101...
Researchers discover neurons in the brain that controls food intake without causing nausea in an animal modelBy teasing apart the therapeutic benefits from the adverse effects of glucagon-like peptide-1 receptor (GLP1R) agonists, researchers from...